License Agreements |
3 Months Ended |
|---|---|
Aug. 31, 2020 | |
| License Agreements |
Note 9 – License Agreements The Company has two license agreements with a third-party licensor covering the licensor’s “system
know-how” technology with respect to the Company’s use of proprietary cell lines to manufacture new leronlimab (PRO 140) material. The Company accrues annual license fees of £600,000 (approximately US$774,000 utilizing current exchange rates), which fees are payable annually inits first commercial sale, which will continue as long as the license agreement is maintained. |
| X | ||||||||||
- Definition The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|